Pfizer's Lipitor Patent Invalidated In South Korea

Law360, New York (June 26, 2008, 12:00 AM EDT) -- A South Korean court has reportedly ruled against Pfizer Inc. in a patent suit over the blockbuster cholesterol-reducing drug Lipitor.

A South Korean court on Thursday upheld an earlier ruling that Pfizer's Lipitor patent was invalid and that the generic made by five South Korean pharmaceutical companies did not breach the patent, Reuters reported.

Korean drug companies producing the generic include Dong-A Pharmaceutical and Boryung Pharmaceutical.

Pfizer plans to appeal the ruling in the Korean Supreme Court.

“We are hopeful that a higher court will reverse...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.